Clinical trial NCT02898350: Surgical Scar Treatment With the Pulsed Dye Laser in Combination With a CO2 Laser
Official title: Multi-Center Study to Compare the Safety and Efficacy of Clearance of Surgical Scars With the Pulse Dye Laser in Combination With a CO2 Laser in a Split Scar Evaluation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Scars
Lead sponsor: Syneron Medical
Sponsor class: INDUSTRY
First posted: 2016-09-13
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Prospective, randomized, split lesion treatment with 4 study Arms to evaluate safety and efficacy of combined treatment for minimizing of surgical scars, including post Moh's surgery.

Detailed description: Prospective, Randomized, Split lesion treatment with 4 study Arms: 1) treatment with pulsed dye laser (PDL) only, 2) treatment with CO2 laser only, 3) PDL and CO2 laser combined treatment, and 4) split scar combined lasers with an additional single CO2 laser treatment immediately post-surgery vs. no treatment.

Eligibility criteria: Inclusion Criteria:

* Comprehension of, and willingness to sign, the Informed Consent Form.
* Have a planned a surgical procedure, which is expected to result in a least one linear surgical scar of at least 3.0 cm.
* Be a healthy male or female of at least 18 years old.
* Fitzpatrick skin type I-V.
* Willingness to follow the treatment and follow-up schedule and the post-treatment care instructions.
* Non pregnant and/or breast feeding, if applicable.
* Willingness to provide a brief medical history including disclosure of any prescribed or over-the-counter medications taken within the past 6 months.
* Agree to follow and undergo all study-related procedures.
* Use of daily use of sunblock SPF 30 or higher for duration of the study.

Exclusion Criteria:

1. Pregnant and/or breastfeeding.
2. Fitzpatrick skin type VI.
3. Prior treatment for the surgical scar to be treated in this study.
4. Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen.
5. Use of Isotretinoin or other systemic retinoids within the past 6 months.
6. Use of topical retinoids or therapeutic topicals in the treatment area in past 2 months.
7. Use of medications that induce photosensitivity on the 595 and 10,600 nm wavelength ranges.
8. Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions.
9. History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
10. Having any uncontrolled disease or disorder or one which per the investigator's judgment might make it unsafe for the subject to participate in this study.
11. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning and sun exposure for the duration of the study.
12. Participation in another investigational device or investigational drug study within 30 days prior to enrollment, as per the investigator's clinical judgment.
13. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Primary outcomes:
measure: Improvement in Global Evaluation Response (GER) scale for 4 study arms compared to baseline
timeFrame: Baseline, 3 months after final treatment
Secondary outcomes:
measure: Improvement in Vancouver Scar Scale (VSS) scale for 4 study arms compared to baseline
timeFrame: Baseline, 3 months after final treatment
Other outcomes:
measure: Number and severity of adverse events
timeFrame: Baseline and up to 3 months after treatment
Locations:
city: Englewood
country: United States
facility: AboutSkin, Dermatology and Derm Surgery PC
state: Colorado
city: New York
country: United States
facility: Laser & Skin Surgery Center of New York
state: New York
Study officials:
affiliation: Syneron Medical
name: Shlomit Mann, MSc
role: STUDY_DIRECTOR
References:
citation: Cohen JL. Minimizing skin cancer surgical scars using ablative fractional Er:YAG laser treatment. J Drugs Dermatol. 2013 Oct;12(10):1171-3.
citation: Weiss ET, Chapas A, Brightman L, Hunzeker C, Hale EK, Karen JK, Bernstein L, Geronemus RG. Successful treatment of atrophic postoperative and traumatic scarring with carbon dioxide ablative fractional resurfacing: quantitative volumetric scar improvement. Arch Dermatol. 2010 Feb;146(2):133-40. doi: 10.1001/archdermatol.2009.358.
citation: Alster T. Laser scar revision: comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. Dermatol Surg. 2003 Jan;29(1):25-9. doi: 10.1046/j.1524-4725.2003.29024.x.